Renal effect of YM435, a new dopamine D1 receptor agonist, in anesthetized dogs

European Journal of Pharmacology

Volumn 322, Issue 1, 1997, Pages 45-53

  Yatsu, Takeyuki ^a   Arai, Yukinori ^a   Takizawa, Kenji ^b   Kasai Nakagawa, Chieko ^a   Takanashi, Masahiro ^a   Uchida, Wataru ^a   Inagaki, Osamu ^a   Tanaka, Akihiro ^a   Asano, Masaharu ^b   Honda, Kazuo ^a   Takenaka, Toichi ^a  

^a Inst for Drug Discovery Research   (Japan)

^b ASTELLAS PHARMA INC   (Japan)

Author keywords

Angiotensin II; Dopamine D1 receptor agonist; PAF (platelet activating factor); Renal nerve stimulation; Renal vasodilator; YM435

Indexed keywords

4 (3,4 DIHYDROXYPHENYL) 1,2,3,4 TETRAHYDRO 7,8 DIHYDROXYISOQUINOLINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; DOPAMINE RECEPTOR STIMULATING AGENT; UNCLASSIFIED DRUG;

ANESTHESIA; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOG; FEMALE; GLOMERULUS FILTRATION RATE; HEART RATE; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; MALE; MEAN ARTERIAL PRESSURE; MICTURITION; NONHUMAN; PRIORITY JOURNAL; SODIUM URINE LEVEL;

(R)-2,3,4,5-TETRAHYDRO-8-CHLORO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL; ANESTHESIA; ANGIOTENSIN II; ANIMALS; DOGS; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRIC STIMULATION; FEMALE; HEMODYNAMIC PROCESSES; INFUSIONS, INTRAVENOUS; ISOQUINOLINES; KIDNEY; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; MALE; PLATELET ACTIVATING FACTOR; RECEPTORS, DOPAMINE D1; RENAL CIRCULATION; TETRAHYDROISOQUINOLINES; VASODILATOR AGENTS;

EID: 0030889840     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(96)00980-6     Document Type: Article

References (36)

1. 1 agonists: 4-(3,4-dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinoline derivatives, Chem. Pharm. Bull. 39, 2910.
2. Anan, H., A. Tanaka, R. Tsuzuki, M. Yokota, T. Yatsu and T. Fujikura, 1996, 4-(3,4-Dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinoline derivatives. II. Their renal vasodilation activity and structure-activity relationship, Chem. Pharm. Bull. 44, 1865.
3. + ATPase activity in rat proximal convoluted tubule segments, Am. J. Physiol. 252, F39.
4. Baer, P.G. and L.M. Cagen, 1987, Platelet activating factor vasoconstriction of dog kidney, Hypertension 9, 253.
5. Brake, T.J., R.E. Cronin, K.L. Duchin, L.N. Peterson and R.W. Schrier, 1980, Ischemic and tubular obstruction during acute renal failure in dogs: mannitol in protection, Am. J. Physiol. 238, F305.
6. 2 receptors in mediating the renal effects of angiotensin II in the anaesthetized dog, Br. J. Pharmacol. 109, 148.
7. DiBona, G.F., 1982, The functions of the renal nerves, Rev. Physiol. Biochem. Pharmacol. 94, 75.
8. DiBona, G.F. and L.L. Sawin, 1971, The renin-angiotensin system in acute renal failure in the rat, Lab. Invest. 25, 528.
9. 125I-SCH 23982, Am. J. Physiol. 255, F970.
10. + exchanger activity in renal BBMV by stimulation of adenylate cyclase, Am. J. Physiol. 259, F297.
11. 1 antagonist SCH 23390, Am. J. Physiol. 249, F236.
12. + exchanger, Am. J. Physiol. 258, F514.
13. 2) in rat renal proximal tubules, Pharmacologist 33, 210p.
14. Goldberg, L.I., Y.Y. Hsieh and L. Resnekov, 1977, Newer catecholamines for treatment of heart failure and shock: an update of dopamine and a first look at dobutamine, Prog. Cardiovasc. Dis. 19, 327.
15. Hahn, R.A., J.R. Wardell, J.R. Henry, M. Sarau and P.T. Ridley, 1982, Characterization of the peripheral and central effects of SF&F 82526, a novel dopamine receptor agonist, J. Pharmacol. Exp. Ther. 223, 305.
16. Harris, P.J., 1992, Regulation of proximal tubule function by angiotensin, Clin. Exp. Pharmacol. Physiol. 19, 213.
17. Jamil, K.M., T. Takano, A. Nakao, Z. Honda, T. Shimizu, T. Watanabe and K. Kurokawa, 1992, Expression of platelet activating factor receptor in renal tubular cell line (LLC-PK1), Biochem. Biophys. Res. Commun. 187, 767.
18. Lokhandwala, M.F. and S.S. Hegde, 1990, Cardiovascular dopamine receptors: role of renal dopamine and dopamine receptors in sodium excretion, Pharmacol. Toxicol. 66, 237.
19. Lokhandwala, M.F., S.J. Vyas and S.S. Hegde, 1990, Renal dopamine and dopamine receptors in the regulation of sodium excretion, J. Auton. Pharmacol. 10 (Suppl. 1), S57.
20. Lopez-Farre, A., M. Torralbo and J.M. Lopez-Novoa, 1988, Glomeruli from ischemic rat kidneys produce increased amounts of platelet activating factor, Biochem. Biophys. Res. Commun. 152, 129.
21. Lopez-Farre, A., F. Bernabeu, D. Gomez-Garre, S. Ramon y Cajal, P. Braquet and J.M. Lopez-Novoa, 1990, Platelet-activating factor antagonists treatment protects against postischemic acute renal failure in rats, J. Pharmacol. Exp. Ther. 253, 328.
22. Makabali, C., M.H. Weil and R.J. Henning, 1982, Dobutamine and other sympathomimetic drugs for the treatment of low cardiac output failure, Semin. Anesth. 1, 63.
23. McDonald, R.H., L.I. Goldberg, J.L. McNay and E.P. Tuttle, 1964, Effects of dopamine in man: augmentation of sodium excretion, glomerular filtration rate, and renal plasma flow, J. Clin. Invest. 43, 1116.
24. Navar, L.G., G. Saccomani and K.D. Mitchell, 1991, Synergistic intrarenal actions of angiotensin on tubular reabsorption and renal hemodynamics, Am. J. Hypertens. 4, 90.
25. Osborn, J.L., H. Holdass, M.D. Thomas and G.F. DiBona, 1983, Renal adrenoceptor mediation on antidiuresis and renin secretion responses to low frequency renal nerve stimulation in dogs, Circ. Res. 53, 298.
26. Plante, G.E., R.L. Hebert, C. Lamoureux, P. Braquet and P. Sirois, 1986, Hemodynamic effects of PAF-acether, Pharmacol. Res. Commun. 18 (Suppl.), 173.
27. Plante, G.E., P. Sirois and P. Braquet, 1988, Platelet activating factor antagonism with BN52021 protects the kidney against acute ischemic injury, Prostaglandins Leukotrienes Essent. Fatty Acids 34, 53.
28. Prewitt, P.L., B.E. Leach, L.W. Byers, B. Brooks, W.E.M. Lands and E.E. Muirhead, 1979, Antihypertensive polar renomedullary lipid, a semisynthetic vasodilator, Hypertension 1, 299.
29. Sherf, H., A.S. Nies, U. Schwertschlag, M. Hughes and J.G. Gerber, 1987, Hemodynamic effects of platelet activating factor in the dog kidney in vivo, Hypertension 8, 737.
30. Siragy, H.M., R.A. Felder, N.E. Howell, R.L. Chevalier, M.J. Peach and R.M. Carey, 1988, Intrarenal dopamine acts at the dopamine-1 receptor to control renal function, J. Hypertens. 6 (Suppl. 4), S479.
31. 1) agonist, YM435, J. Pharmacol. Exp. Ther. 264, 1154.
32. Traniger, B.S., S.M. Rosen, A. Grandchamp, H. Strebel and H.R. Kriek, 1971, Redistribution of renal blood flow in hemorrhagic hypotension: role of renal nerves and circulating catecholamines, Eur. J. Clin. Invest. 1, 277.
33. Wang, J. and M.J. Dunn, 1987, Platelet-activating factor mediates endotoxin-induced acute renal insufficiency in rats, Am. J. Physiol. 253, F1283.
34. 1 receptor agonist activity of YM435 in the canine renal vasculature, Gen. Pharmacol. (in press).
35. 1 receptor agonist, in anesthetized dogs, J. Cardiovasc. Pharmacol. (in press).
36. 3H]-SCH 23390 labels dopamine D-1 receptor sites in the rat kidney, Eur. J. Pharmacol. 164, 159.